Novartis said Friday it has pulled its irritable bowel treatment Zelnorm (tegaserod maleate) off the US market after new clinical data showed an increased risk of cardiovascular events in patients ...
An investment in promotional strategy has helped fuel new prescription growth for Novartis brands Diovan and Zelnorm, chief marketing officer Kurt Graves said yesterday during UBS’ Global Life ...
Novartis pulled bowel drug Zelnorm from U.S. shelves on Friday at the request of regulators because clinical trial data indicated a possible link to heart attacks and strokes. The move is a body blow ...
Novartis ' Zelnorm, approved by U.S. regulators in July, could well reach annual sales of $1 billion or more. But in order for that to happen, Novartis has to convince gun-shy doctors that the drug is ...
The U.S. Food and Drug Administration has asked Novartis to stop selling its chronic constipation drug Zelnorm after combining 29 clinical studies turned up an increased cardiovascular risk. The ...
Zelnorm was a steady seller for Novartis before cardiovascular red flags led to the irritable bowel syndrome (IBS) med’s collapse. Now—more than a decade after its recall and with new owners—Zelnorm's ...
BEDMINSTER, N.J.--(BUSINESS WIRE)--Alfasigma USA, Inc. today announced that ZELNORM™ (tegaserod) is now available in the United States as a prescription pharmaceutical treatment for irritable bowel ...
LONDON (CBS.MW) -- Swiss pharmaceutical Novartis said a study presented at the 2004 United European Gastroenterology Week shows its Zelnorm irritable bowel syndrome drug is effective and ...
US WorldMeds announced that the Food and Drug Administration (FDA) has approved the reintroduction of Zelnorm (tegaserod) for the treatment of irritable bowel syndrome with constipation (IBS-C) in ...
Goodbye cruel world. Novartis is pulling the irritable bowel med Zelnorm off the market almost completely, saying it will supply the drug only for emergency use. And even in emergencies, Zelnorm will ...
BASEL (MarketWatch) -- Novartis AG NVS Friday said it will suspend sales and marketing for its irritable bowel drug Zelnorm after the U.S. Food and Drug Administration asked for more discussion on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results